Glaxosmithkline $3 bn Settlement

            
 
Business Ethics Case Studies|MBA Management Case Studies |Business Ethics Case Study|Ethics Case Studies

ICMR HOME | Case Studies Collection

Case Details:

Case Code : BECG126
Case Length : 21 Pages
Period : 1998-2012
Organization : GlaxoSmithKline
Pub Date : 2013
Teaching Note :Available
Countries : US
Industry : Pharmaceutical Industry

To download Glaxosmithkline $3 bn Settlement case study (Case Code: BECG126) click on the button below and select the case from the list of available cases:

Business Ethics Case Studies | Case Study in Management, Operations, Strategies, Business Ethics, Case Studies

OR


Buy With PayPal

Amount to be paid:



Prefer to pay in another currency ?
Select Currency for Payment



Exchange Rates: Click Here
Delivery Details: Click Here

Price:

For delivery in electronic format: Rs. 500 ;
For delivery through Shipping & Handling Charges extra: Rs. 500 +Shipping & Handling Charges extra

Business Ethics Case Studies
Case Studies Collection
ICMR Home
View Detailed Pricing Info
How To Order This Case
Business Case Studies
Case Studies by Area
Case Studies by Industry
Case Studies by Company

Google
Webicmrindia.org


Please note:

This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.



Chat with us

Strategic Management Formulation, Implementation, & Control, 12e

Please leave your feedback

Leave Your Feedback

ICMR India ICMR India ICMR India ICMR India RSS Feed

<< Previous

Global pharmaceutical company, Glaxo1 SmithKline2 (GSK) on 02 July 2012 had agreed to pay $3 billions in fines and pleaded guilty to criminal charges for illegally promoting its best selling anti-depressants drugs for unapproved uses to Food and Drug Administration3 (FDA)4. The pharmaceutical company was also accused of overcharging the US national health care program, Medicaid5 , and for allegedly paying kickbacks to doctors who prescribed some of its drugs.Though GSK did not admit to any wrong doing in the civil settlement, according to the US Justice Department, on July 2, 2012, the pharmaceutical company had agreed to plead guilty to criminal charges for promoting its anti-depressants drugs Paxil and Wellbutrin for children and adolescents despite the drugs not being approved by the FDA.6

Business Ethics Case Studies | Case Study in Management, Operations, Strategies, Business Ethics, Case Studies

The company also pleaded guilty for failing to report safety data about its top selling diabetic drug Avandia. The diabetes drug was banned in the year 2007 in Europe after it was found that its intake sharply increased the risk of having heart attacks and congestive heart failure. The drug was also restricted in the US on the same grounds.

The pharmaceutical firm pleaded guilty to three counts of criminal misdemeanor - two counts to introducing the misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count to failing to report on the safety data about the drug Avandia to the FDA. GSK agreed to pay $3 bn as fines to absolve from criminal and civil liabilities.7

The US Justice Department in its notification about the settlement, described it as the largest healthcare fraud settlement in US history.8 Briefing the press about the settlement charges, James M. Cole, deputy attorney general of the US Justice Department, Washington, said that the fine was unprecedented in both size and scope and was a clear warning to pharmaceutical companies committing healthcare frauds.9 At a press conference after the settlement, assistant attorney general, Stuart F. Delerly, said that the fine was levied not only to punish the wrong doer and recover taxpayer dollars but also to ensure GSK’s future compliance with the law. GSK CEO Sir Andrew Witty (Witty) in a press note commented that the company had learned from the mistakes that it had made.10

Introduction Contd...- Next Page>>


1] Glaxo was founded in New Zealand in 1873 by Joseph Nathan. In 1995, it took over Burrough Wellcome to form GlaxoWellcome.
2] SmithKline Beckman merged with Beecham in 1989 to form SmithKlineBeecham. Later, on 17 January, 2000, GlaxoWellcome and SmithKlineBeecham merged to form GlaxoSmithKline (GSK).
3] The FDA is the consumer protection agency in the US. FDA protects and monitors medical devices, food, drugs, vaccines, blood and biologics, animal & veterinary cosmetics, radiation-emitting products and tobacco products.
4] Linda A. Johnson, "GlaxoSmithKline to pay $3B for health fraud," www.guardian.co.uk, July 03, 2012
5] Medicaid is a US national healthcare program, which pays for medical services for low-income people. Medicaid is paid to providers of healthcare - doctors, hospitals and pharmacists.
6] Department of Justice, US, "GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data," www.justice.gov, July 12, 2012.
7] Reports, "Drug gaint Glaxo pleads guilty, fined $3B for drug marketing", usatoday30.usatoday.com, July 92, 2012, accessed on November 12.
8] Chris Woollams, "Glaxo in the largest ever US drug fraud settlement," www.canceractive.com, accessed on October 29, 2012.
9] Sharise Cruz, "GalxoSmithKline Agrees to $3billion Fraud Settlement," www. bussinessreviewusa.com, July 3, 2012.
10] Jesse J.Holland, "GlaxoSmithKline to pay $3B for health fraud," Associated Press, July 2, 2012

Google





Business Ethics and Corporate Governance Textbook
Text Book - Rs. 500
Textbooks Collection

Business Ethics and Corporate Governance Workbook
Work Book - Rs. 500
Workbooks Collection

Case Studies in Business Ethics - Vol. I

e-Book in Business Ethics
e-Book in Business Ethics

Case Study Volumes Collection

 

Case Studies Links:- Case Studies, Short Case Studies, Simplified Case Studies.

Other Case Studies:- Multimedia Case Studies, Cases in Other Languages.

Business Reports Link:- Business Reports.

Books:- Textbooks, Work Books, Case Study Volumes.